Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
AstraZeneca’s CHOICE Survey Targets Real-World Drivers of EGFR-TKI Use in China
AstraZeneca’s CHOICE study is a non-interventional survey exploring factors influencing Chinese doctors’ and patients’ decisions for first-line EGFR-TKI treatments for advanced non-small cell lung cancer. The study aims to understand preferences regarding efficacy, side effects, cost, and convenience, to sharpen AstraZeneca’s marketing and positioning in China’s competitive EGFR market. While ongoing, the study is descriptive and market-focused rather than testing new drugs, providing insights into prescribing patterns and preference trends.